Synflorix News and Research

RSS

PCV10 vaccine against pneumonia sharply reduces incidence of serious pneumococcal disease

A vaccine against Streptococcus pneumoniae, a major cause of childhood illness and mortality in the developing world, sharply reduced the incidence of serious pneumococcal disease among children in a large Kenyan community after it was introduced in 2011, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health.

17 Apr 2019

New vaccine for pneumonia holds promise to save thousands of lives

In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

20 Oct 2017

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

GAVI chair calls for greater reductions in vaccine prices for developing countries

On Monday, the same day the GAVI Alliance helped oversee the roll out of a routine pneumococcal vaccine in Kenya, GAVI chairman Dagfinn Hoybraten highlighted the need for greater reductions in vaccine prices in developing countries during an interview with Reuters, the news service reports. The piece examines the funding mechanism in place to finance the pneumococcal vaccines, known as Advance Market Commitment (AMC), as well as the budget shortfall facing the group (Kelland, 2/14).

16 Feb 2011

Pneumococcal vaccine officially rolled out in Kenya

"Kenya on Monday became the first African country to introduce a routine vaccine against pneumococcal disease, which claims the lives of more than half a million children under five each year," Deutsche Presse Agentur/The Hindu reports. The GAVI Alliance, which is supporting the vaccine's roll out, "is aiming to introduce the vaccine to 19 developing countries - including Nicaragua, Guyana, Yemen and Sierra Leone - within a year and hopes to reach more than 40 nations by 2015, depending on funding."

15 Feb 2011

GAVI Alliance launches pneumonia vaccine project in Nicaragua

"A new vaccine against the most deadly forms of pneumonia, one of the world's biggest killers of children, [was] launched in Nicaragua [on Sunday] as part of an effort to prevent 700,000 deaths in poorer countries by 2015," Reuters reports (Kelland, 12/10).

14 Dec 2010

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a "10-year deal … to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations," Reuters reports.

25 Mar 2010

Vaccine deal signed - 47 developing countries to receive low priced vaccines by 2015

Pharmaceutical giants have signed a historical 10-year deal on Tuesday pledging the supply of 60 million doses a year of pneumococcal vaccines at cut-prices to developing nations.

24 Mar 2010

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

GSK has become one of the first manufacturers to sign a unique agreement with the GAVI Alliance that has the potential to save millions of children from dying in the world's poorest countries. GSK will supply up to 300 million doses of its vaccine Synflorix, for invasive pneumococcal disease, to GAVI over a ten year period. Pneumococcal disease is a leading cause of death in children under the age of five in developing countries.

24 Mar 2010

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.

29 Sep 2009